Open AccessSpironolactone as an Adjunctive Treatment in Neovascular Age-Related Macular Degeneration
Author(s) -
Kapil Kapoor,
Jennifer Sim
Publication year - 2017
Publication title -
case reports in ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.299
H-Index - 17
ISSN - 1663-2699
DOI - 10.1159/000475880
Subject(s) - medicine , macular degeneration , ranibizumab , serous fluid , ophthalmology , choroidal neovascularization , aflibercept , endophthalmitis , adjunctive treatment , intensive care medicine , pediatrics , surgery , bevacizumab , chemotherapy
Neovascular age-related macular degeneration (AMD) is a potentially sight-threatening condition. The current standard-of-care treatment regimen is serial intravitreal antivascular endothelial growth factor injections. While these typically have great success, they do carry exceptional treatment burden on the patient, cost burden due to their required frequency of use, and the risk of endophthalmitis, which can be devastating. This case report explores an alternative potential option as a treatment adjunct for neovascular AMD (nAMD), and identifies some of the overlap between nAMD and central serous chorioretionpathy. Future research is needed to better understand the role of mineralocorticoid receptor antagonist treatment in this disease spectrum.